Evidence‑Based Management of Intertrigo

Candidal Intertrigo – Mild Disease

• In patients with mild secondary candidal infection of skin folds, topical azole therapy such as clotrimazole troches (10 mg, five times daily) or a miconazole muco‑adhesive tablet (50 mg once daily) for 7–14 days reduces erythema and pruritus. 1
• When azole therapy is unsuitable, a nystatin suspension (≈100 000 U/mL, 4–6 mL four times daily) for 7–14 days provides comparable clinical improvement. 2

Candidal Intertrigo – Moderate to Severe Disease

• For extensive or refractory candidal intertrigo, oral fluconazole (100–200 mg once daily) administered for 7–14 days leads to resolution of lesions in the majority of cases. 3

Fluconazole‑Refractory Candidal Intertrigo

• In patients who do not respond to fluconazole, itraconazole solution (200 mg once daily) for an appropriate course achieves clinical cure. 1
• An alternative regimen uses posaconazole suspension (400 mg twice daily for 3 days, then 400 mg daily) for up to 28 days, which has demonstrated efficacy in resistant cases. 2

Gram‑Negative Bacterial Intertrigo

• For erosive, weeping intertrigo of the toe‑webs colonised by Pseudomonas aeruginosa or other gram‑negative organisms, a combination of a moderate‑potency topical corticosteroid and an appropriate topical antimicrobial is recommended; treatment typically extends 56–61 days to achieve sustained clearance. 3

Management of Recurrent Candidal Intertrigo

• Chronic suppressive antifungal therapy is generally unnecessary for most patients with recurrent candidal intertrigo. 1
• If suppression is required, intermittent fluconazole (100 mg three times weekly) can be used to prevent recurrence without continuous daily dosing. 4

Special Considerations in HIV‑Infected Patients

• Initiation and maintenance of antiretroviral therapy is strongly advised for HIV‑positive individuals, as it markedly reduces the incidence of recurrent intertrigo episodes. 4